{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2014:JJN2AKV6TEJVG7UGKFBFNSZC6F","short_pith_number":"pith:JJN2AKV6","canonical_record":{"source":{"id":"1402.6962","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2014-02-27T16:38:23Z","cross_cats_sorted":[],"title_canon_sha256":"ff5adad6a18753e5ebf2276a78897c3a0556aa596047e1873d288896a320158b","abstract_canon_sha256":"7fd845866d0306994419a3ccf7c8d0d37314fbfcfc49323ec4503d1ca1fbb551"},"schema_version":"1.0"},"canonical_sha256":"4a5ba02abe9913537e86514256cb22f17770101364dec67cec87242ae3a47a25","source":{"kind":"arxiv","id":"1402.6962","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1402.6962","created_at":"2026-05-18T02:20:47Z"},{"alias_kind":"arxiv_version","alias_value":"1402.6962v1","created_at":"2026-05-18T02:20:47Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1402.6962","created_at":"2026-05-18T02:20:47Z"},{"alias_kind":"pith_short_12","alias_value":"JJN2AKV6TEJV","created_at":"2026-05-18T12:28:33Z"},{"alias_kind":"pith_short_16","alias_value":"JJN2AKV6TEJVG7UG","created_at":"2026-05-18T12:28:33Z"},{"alias_kind":"pith_short_8","alias_value":"JJN2AKV6","created_at":"2026-05-18T12:28:33Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2014:JJN2AKV6TEJVG7UGKFBFNSZC6F","target":"record","payload":{"canonical_record":{"source":{"id":"1402.6962","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2014-02-27T16:38:23Z","cross_cats_sorted":[],"title_canon_sha256":"ff5adad6a18753e5ebf2276a78897c3a0556aa596047e1873d288896a320158b","abstract_canon_sha256":"7fd845866d0306994419a3ccf7c8d0d37314fbfcfc49323ec4503d1ca1fbb551"},"schema_version":"1.0"},"canonical_sha256":"4a5ba02abe9913537e86514256cb22f17770101364dec67cec87242ae3a47a25","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T02:20:47.542754Z","signature_b64":"MCFoDDS1lHW2RD1qGbO9mAtgYugrO0LEbXBYuSbdL1oHh9UKU/IFTemisWBZ9i912ITBcH9w9pqN8uRLwXD8Cw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"4a5ba02abe9913537e86514256cb22f17770101364dec67cec87242ae3a47a25","last_reissued_at":"2026-05-18T02:20:47.542044Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T02:20:47.542044Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1402.6962","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T02:20:47Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"+xZej0k0Ezz823C/+m/2OPKeSQ8x0uD6t0xd/UOQUz42Lu1c/Mg+fcjiP5AiyuSy4ZPijwwEOD2b1ugfhsq+AA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-30T13:56:45.757308Z"},"content_sha256":"2eb4f7d0e3338d038e6f31bcdb8ad65617173aa9e05778008f2ff848be570a20","schema_version":"1.0","event_id":"sha256:2eb4f7d0e3338d038e6f31bcdb8ad65617173aa9e05778008f2ff848be570a20"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2014:JJN2AKV6TEJVG7UGKFBFNSZC6F","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.AP","authors_text":"Lorenzo Trippa, Peter M\\\"uller, Yanxun Xu, Yuan Ji","submitted_at":"2014-02-27T16:38:23Z","abstract_excerpt":"Targeted therapies based on biomarker profiling are becoming a mainstream direction of cancer research and treatment. Depending on the expression of specific prognostic biomarkers, targeted therapies assign different cancer drugs to subgroups of patients even if they are diagnosed with the same type of cancer by traditional means, such as tumor location. For example, Herceptin is only indicated for the subgroup of patients with HER2+ breast cancer, but not other types of breast cancer. However, subgroups like HER2+ breast cancer with effective targeted therapies are rare and most cancer drugs "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1402.6962","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T02:20:47Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"RIgUyRMaxQNvNbmXq4d9UUhDD09Rqd9HU2E99OY7MsB0BxlzWsojxFTbxuEYdrLeBs5gmikS7dma1BCnSyMJDw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-30T13:56:45.757797Z"},"content_sha256":"ccc58b4f7af890a4567a3227cc93ad6c17c66d0b1aabeac3a165814fa5ec92a5","schema_version":"1.0","event_id":"sha256:ccc58b4f7af890a4567a3227cc93ad6c17c66d0b1aabeac3a165814fa5ec92a5"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F/bundle.json","state_url":"https://pith.science/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-30T13:56:45Z","links":{"resolver":"https://pith.science/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F","bundle":"https://pith.science/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F/bundle.json","state":"https://pith.science/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F/state.json","well_known_bundle":"https://pith.science/.well-known/pith/JJN2AKV6TEJVG7UGKFBFNSZC6F/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2014:JJN2AKV6TEJVG7UGKFBFNSZC6F","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"7fd845866d0306994419a3ccf7c8d0d37314fbfcfc49323ec4503d1ca1fbb551","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2014-02-27T16:38:23Z","title_canon_sha256":"ff5adad6a18753e5ebf2276a78897c3a0556aa596047e1873d288896a320158b"},"schema_version":"1.0","source":{"id":"1402.6962","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1402.6962","created_at":"2026-05-18T02:20:47Z"},{"alias_kind":"arxiv_version","alias_value":"1402.6962v1","created_at":"2026-05-18T02:20:47Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1402.6962","created_at":"2026-05-18T02:20:47Z"},{"alias_kind":"pith_short_12","alias_value":"JJN2AKV6TEJV","created_at":"2026-05-18T12:28:33Z"},{"alias_kind":"pith_short_16","alias_value":"JJN2AKV6TEJVG7UG","created_at":"2026-05-18T12:28:33Z"},{"alias_kind":"pith_short_8","alias_value":"JJN2AKV6","created_at":"2026-05-18T12:28:33Z"}],"graph_snapshots":[{"event_id":"sha256:ccc58b4f7af890a4567a3227cc93ad6c17c66d0b1aabeac3a165814fa5ec92a5","target":"graph","created_at":"2026-05-18T02:20:47Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Targeted therapies based on biomarker profiling are becoming a mainstream direction of cancer research and treatment. Depending on the expression of specific prognostic biomarkers, targeted therapies assign different cancer drugs to subgroups of patients even if they are diagnosed with the same type of cancer by traditional means, such as tumor location. For example, Herceptin is only indicated for the subgroup of patients with HER2+ breast cancer, but not other types of breast cancer. However, subgroups like HER2+ breast cancer with effective targeted therapies are rare and most cancer drugs ","authors_text":"Lorenzo Trippa, Peter M\\\"uller, Yanxun Xu, Yuan Ji","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2014-02-27T16:38:23Z","title":"Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1402.6962","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:2eb4f7d0e3338d038e6f31bcdb8ad65617173aa9e05778008f2ff848be570a20","target":"record","created_at":"2026-05-18T02:20:47Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"7fd845866d0306994419a3ccf7c8d0d37314fbfcfc49323ec4503d1ca1fbb551","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2014-02-27T16:38:23Z","title_canon_sha256":"ff5adad6a18753e5ebf2276a78897c3a0556aa596047e1873d288896a320158b"},"schema_version":"1.0","source":{"id":"1402.6962","kind":"arxiv","version":1}},"canonical_sha256":"4a5ba02abe9913537e86514256cb22f17770101364dec67cec87242ae3a47a25","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"4a5ba02abe9913537e86514256cb22f17770101364dec67cec87242ae3a47a25","first_computed_at":"2026-05-18T02:20:47.542044Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T02:20:47.542044Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"MCFoDDS1lHW2RD1qGbO9mAtgYugrO0LEbXBYuSbdL1oHh9UKU/IFTemisWBZ9i912ITBcH9w9pqN8uRLwXD8Cw==","signature_status":"signed_v1","signed_at":"2026-05-18T02:20:47.542754Z","signed_message":"canonical_sha256_bytes"},"source_id":"1402.6962","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:2eb4f7d0e3338d038e6f31bcdb8ad65617173aa9e05778008f2ff848be570a20","sha256:ccc58b4f7af890a4567a3227cc93ad6c17c66d0b1aabeac3a165814fa5ec92a5"],"state_sha256":"11bce2a07ea2896f601c2d1d020daf0c1e3912c84f2cbc8672dd69bbab18d328"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"78VXtxNHQJEBgpeaDIRuHznlsTlcyU0+QKe01kJcBvg/QmuIC78ldr5Bj43ZtB3x1bZiENAzMizpf1e58ntxDQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-30T13:56:45.760610Z","bundle_sha256":"517ecbfead92c5c7d5d959618c271aa1a2b8f97198b4760bb53bef6c7fd220d7"}}